Krystal Biotech Company Insiders
| KRYS Stock | USD 147.49 2.66 1.77% |
Krystal Biotech employs about 275 people. The company is managed by 19 executives with a total tenure of roughly 642 years, averaging almost 33.0 years of service per executive, having 14.47 employees per reported executive. Breaking down Krystal Biotech's management performance can provide insight into the firm performance.
Krystal Biotech Management Team Effectiveness
The company has return on total asset (ROA) of 0.0866 % which means that it generated a profit of $0.0866 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.139 %, meaning that it created $0.139 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Krystal Biotech Workforce Comparison
Krystal Biotech is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 4,168. Krystal Biotech holds roughly 275 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.37 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.41 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.41. Krystal Biotech Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Krystal Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Krystal Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Krystal Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Krystal Biotech Notable Stakeholders
A Krystal Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Krystal Biotech often face trade-offs trying to please all of them. Krystal Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Krystal Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Suma Krishnan | President Founder | Profile | |
| Josh Suskin | Director Operations | Profile | |
| Christine Wilson | Head Marketing | Profile | |
| David Chien | Senior Development | Profile | |
| Hubert MD | Senior Development | Profile | |
| Gloria Lin | Accounting Mang | Profile | |
| Kathryn Romano | Executive Officer | Profile | |
| Katherine Tuminello | HR Mang | Profile | |
| Stephane Paquette | Vice Development | Profile | |
| Jennifer McDonough | Analytics Access | Profile | |
| MS MBA | Chairman, Founder | Profile | |
| John Karakkal | Vice Marketing | Profile | |
| Ram Kamineni | Senior Operations | Profile | |
| David Glynn | Commercial Counsel | Profile | |
| John Thomas | General Secretary | Profile | |
| Laurent Goux | Senior Europe | Profile | |
| Andreas Orth | Ex Officer | Profile | |
| Meg Dodge | Vice Communications | Profile | |
| Kathryn CPA | Executive Officer | Profile |
About Krystal Biotech Management Performance
The success or failure of an entity such as Krystal Biotech often depends on how effective the management is. Krystal Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Krystal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Krystal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.
Please note, the imprecision that can be found in Krystal Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Krystal Biotech. Check Krystal Biotech's Beneish M Score to see the likelihood of Krystal Biotech's management manipulating its earnings.
Krystal Biotech Workforce Analysis
Traditionally, organizations such as Krystal Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Krystal Biotech within its industry.Krystal Biotech Manpower Efficiency
Return on Krystal Biotech Manpower
| Revenue Per Employee | 1.1M | |
| Revenue Per Executive | 15.3M | |
| Net Income Per Employee | 324.2K | |
| Net Income Per Executive | 4.7M | |
| Working Capital Per Employee | 2.3M | |
| Working Capital Per Executive | 33.7M |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.